RxDoctor Payments Data

George Lanske, MD

Allergy · Billings, MTNPI 1053353755

Payments from drug & device makers

$1,599in general payments, 2019–2025

Across 58 payments — averaging $27.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$278
  • AstraZeneca$255
  • Biocryst US Sales Co., LLC$250
  • GSK$174
  • Genentech USA, Inc.$129
  • CSL Behring$112
  • plus $400 from 8 others

What the payments were for

  • Food & beverage$1,40188%
  • Education$19812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few allergy providers in Montanato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$41,561
Medicare patients
214
Services billed
1,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab102$272,229
Fasenra PenBenralizumab31$171,838
TezspireTezepelumab-Ekko39$165,090
Dupixent PenDupilumab40$139,719
Spiriva RespimatTiotropium Bromide29$28,474
Spiriva HandihalerTiotropium Bromide31$16,142
Advair HfaFluticasone Propion/Salmeterol36$14,804
SymbicortBudesonide/Formoterol Fumarate37$14,143
Breo ElliptaFluticasone/Vilanterol17$13,155
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$9,467
Arnuity ElliptaFluticasone Furoate30$8,637
Fluticasone Propionate HfaFluticasone Propionate15$8,566
Incruse ElliptaUmeclidinium Bromide13$7,893
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$6,937
Epinephrine33$6,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire, Symbicort$255$179,23276 claims
GSKBreo Ellipta, Arnuity Ellipta, Incruse Ellipta$174$29,68560 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Montanaon file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →